Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

19 de noviembre de 2026 actualizado por: ScandiBio Therapeutics AB

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Consenting participants will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 7 days prior to randomisation and start of investigational medicinal product (IMP) administration.

Eligible participants will be randomised on Day 1 (Visit 2) to 4 weeks of twice daily (b.i.d.) oral treatment of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The participants will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose.

Visits at the study site will be performed at Day 1 (Visit 2), Day 14 (Visit 4) and Day 28 (Visit 6; end of in study treatment). There will be telephone follow up visits at Day 7 (Visit 3) and Day 21(Visit 5) checking safety, concomitant medications and IMP compliance. A final follow-up visit for safety assessments will be conducted in a subgroup of patients 14 days after the end of treatment (Day 42; Visit 7) during an IMP-free follow-up period to assess safety and concomitant medications.

The following clinical scales will be used to evaluate the effect of CMA2 on uric acid decline, hsCRP and daily life activity: Serum Uric Acid Levels, hsCRP, number of flares according to the GAFFO criteria, HAQ-DI, SF-36, PGA (100 mm).

Plasma samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis.

Optionally, synovial samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis. Optionally, gut and saliva samples will be collected for metagenomics analysis of gut and oral microbiome.

Laboratory and clinical safety parameters will be monitored at pre-specified time-points.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

336

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Gökhan Gönenli, Uzm. Dr. M.
  • Número de teléfono: + 90 532 405 76 82
  • Correo electrónico: mgonenli@ku.edu.tr

Copia de seguridad de contactos de estudio

  • Nombre: Müjdat Zeybel, Prof. Dr.
  • Número de teléfono: + 90 532 604 83 81
  • Correo electrónico: mzeybel@ku.edu.tr

Ubicaciones de estudio

      • Ankara, Turquía (Türkiye)
        • Aún no reclutando
        • Ankara Bilkent City Hospital
        • Contacto:
          • Hakan Babaoğlu
        • Investigador principal:
          • Hakan Babaoğlu, Assoc. Prof. Dr.
      • Antalya, Turquía (Türkiye)
        • Aún no reclutando
        • Alanya Training and Research Hospital
        • Contacto:
          • Şakir Özgür Keskek
        • Investigador principal:
          • Şakir Özgür Keskek, Prof. Dr.
      • Erzurum, Turquía (Türkiye)
        • Aún no reclutando
        • Atatürk University Research Hospital
        • Contacto:
          • Bülent Albayrak
        • Investigador principal:
          • Bülent Albayrak, Assoc. Prof. Dr.
      • Erzurum, Turquía (Türkiye)
        • Aún no reclutando
        • Erzurum City Hospital
        • Contacto:
          • Kenan Çadırcı
        • Investigador principal:
          • Kenan Çadırcı, Prof. Dr.
      • Eskişehir, Turquía (Türkiye)
        • Reclutamiento
        • Eskişehir Osmangazi University Faculty of Medicine Hospital
        • Contacto:
          • Nazife Şule Bige Yaşar
        • Investigador principal:
          • Nazife Şule Bige Yaşar, Prof. Dr.
      • Istanbul, Turquía (Türkiye)
        • Aún no reclutando
        • Göztepe Prof. Dr. Süleyman Yalçın City Hospital
        • Contacto:
          • Esen Kasapoğlu
        • Investigador principal:
          • Esen Kasapoğlu, Prof. Dr.
      • Istanbul, Turquía (Türkiye)
        • Aún no reclutando
        • Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
        • Contacto:
          • Gülen Hatemi
        • Investigador principal:
          • Gülen Hatemi, Prof. Dr.
      • Istanbul, Turquía (Türkiye)
        • Aún no reclutando
        • Kanuni Sultan Süleyman Training and Research Hospital
        • Contacto:
          • Ozan Cemal İçaçan
        • Investigador principal:
          • Ozan Cemal İçaçan, Specialist. Dr.
      • Istanbul, Turquía (Türkiye)
        • Aún no reclutando
        • Kartal Dr. Lütfi Kırdar City Hospital
        • Contacto:
          • Mehmet Engin Tezcan
        • Investigador principal:
          • Mehmet Engin Tezcan, Specialist. Dr.
      • Istanbul, Turquía (Türkiye)
        • Reclutamiento
        • Koç University Hospital
        • Contacto:
        • Investigador principal:
          • Gökhan Gönenli, Specialist. Dr.
      • Istanbul, Turquía (Türkiye)
        • Aún no reclutando
        • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
        • Contacto:
          • Kadem Arslan
        • Investigador principal:
          • Kadem Arslan, Assoc. Prof. Dr.
      • Istanbul, Turquía (Türkiye)
        • Aún no reclutando
        • Sultan 2nd Abdülhamid Han Training and Research Hospital
        • Contacto:
          • Memnune Sena Ulu
        • Investigador principal:
          • Memnune Sena Ulu, Prof. Dr.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years.
  3. Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria.
  4. Able to give written informed consent for participation in the study by the patient and/or legal representatives.

Exclusion Criteria:

  1. Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion.

  2. Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period.

  3. History of stroke.

  4. History of brain trauma < 14 days.

  5. Uncontrolled diagnosed depression.

  6. Uncontrolled diabetes (HbA1c > 8.4%).

  7. Severe swallowing problems.

  8. PEG-feeding.

  9. Chronic diarrhoea.

  10. Chronic kidney disease with S-creatinine > 1.30 mg/dL.

  11. Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase

  12. Active bronchial asthma at the time of screening.

  13. History of phenylketonuria

  14. Known allergy for substances used in the study

  15. Known allergy for strawberry

  16. Known active malignancy

  17. Known active psoriasis

  18. Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.

  19. Use of anti-microbial agents later than one (1) week prior to inclusion.

  20. Drug and/or alcohol abuse.

  21. Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.

  22. Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

  23. Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)

  24. Females of childbearing potential who:

    Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device or intrauterine hormone-releasing system (IUS)
    • a contraceptive implant
    • an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
    • have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation.

    It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.

    NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).

  25. Male participants who:

    1. Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or
    2. Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product.
  26. Currently has secondary hyperuricemia:

1) Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study.

  • Dietary and physical therapy for the underlying disease
  • Drugs or containing compound preparations that potentially affect SUA level:
  • Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
  • Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
  • Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
  • Antihypertensives (losartan potassium)
  • Diuretics (thiazide diuretics, loop diuretics)
  • Sodium-dependent glucose transporter (SGLT) 2 inhibitors
  • Theophylline

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Brazo de tratamiento

A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

Comparador de placebos: Brazo de placebo

As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
Periodo de tiempo: 4 weeks

Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).

4 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo.
Periodo de tiempo: 4 weeks

Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity.

4 weeks
To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo.
Periodo de tiempo: 4 weeks

Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment.

4 weeks
To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL.
Periodo de tiempo: 4 weeks

Proportion of patients with a serum uric acid level <6 .0 mg/dL at end-of-treatment.

4 weeks
To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo.
Periodo de tiempo: 2 weeks

Change in serum uric acid levels from baseline to 2-weeks.

2 weeks
To evaluate patient adherence to the twice-daily treatment regimen.
Periodo de tiempo: 4 weeks

Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts.

4 weeks
To evaluate the incidence of adverse events (AEs).
Periodo de tiempo: 6 weeks

The percentage of subjects experiencing at least one AE during the study period.

6 weeks
To evaluate the severity of AEs.
Periodo de tiempo: 6 weeks

The incidence of AEs categorized by maximum severity grade.

6 weeks
To evaluate the incidence of serious adverse events (SAEs).
Periodo de tiempo: 6 weeks

The percentage of subjects experiencing at least one SAE during the study period.

6 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Gökhan Gönenli, Uzm. Dr. M., Koc University Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de noviembre de 2026

Finalización primaria (Estimado)

1 de febrero de 2027

Finalización del estudio (Estimado)

1 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

15 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

15 de octubre de 2026

Publicado por primera vez (Actual)

22 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SB-GOUT-001

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .